Sarepta Therapeutics In Strong Uptrend From Exondys 51

Sarepta Therapeutics could get European marketing approval for Exondys 51 at any time which will boost sales. Meanwhile, the company has great growth and is advancing other drugs through its pipeline.

Sarepta Therapeutics stock continues in a strong uptrend on Exondys 51.

Sarepta Therapeutics reported its last quarterly earnings data on October 25, 2017. The company reported EPS of ($0.20) versus the ($0.86) estimate. Revenue also beat coming in at $45.95 million versus the $41.29 million estimate.
Continue reading “Sarepta Therapeutics In Strong Uptrend From Exondys 51”